Clinical trials: HAART-treated
AIDS-Related-Primary Central Nervous System Lymphoma
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
This study will investigate the use of chemotherapy plus highly active antiretroviral therapy (HAART) in patients with Acquired Immunodeficiency Syndrome (AIDS)-related primary brain lymphoma.
- Trial name
- NCT00267865
- Testing
- Methotrexate, Rituximab, Leucovorin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Reduction in Heavy Drinking in Patients With HIV
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
This is a double-blind placebo-controlled study to evaluate the effect of Naltrexone (NTX) and counseling on highly active antiretroviral treatment (HAART) medication adherence in a cohort of HIV-infected patients who report…
- Trial name
- DAWN (NCT01227044)
- Testing
- Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Yale University
HIV Infections
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV…
- Trial name
- NCT00445146
- Testing
- EVG, RTV, ARV regimen
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus, Immune Reconstitution Inflammatory Syndrome
Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
Design: Randomized clinical trial involving hospitalized HIV-1 infected children. Children will be randomized to randomized to urgent (<48 hours) versus early antiretroviral therapy (7-14 days). This trial will be unblinded.
- Trial name
- PUSH (NCT02063880)
- Testing
- Urgent ART, Early ART
- Where
- 4 sites in Kenya
- Volunteers
- 183 people
- Sponsor
- University of Washington
HIV Infections
Helping HIV Infected Patients in South Africa Adhere to Drug Regimens
Three or more anti-HIV drugs are taken in combination as part of a treatment regimen. These drug regimens must be closely followed in order to be successful.
- Trial name
- NCT00076804
- Testing
- Directly Observed Therapy
- Where
- South Africa
- Volunteers
- 274 people
- Sponsor
- Johns Hopkins University
HIV Infections, Lipodystrophy
Therapeutic Approaches to HAART-Induced Lipodystrophy
To determine the efficacy and safety of 4 therapeutic interventions on HAART-Induced lipodystrophy. The interventions are: 1) Dietary - the effect of a high carbohydrate vs.a high cis-monounsaturated fatty acid diet.
- Trial name
- NCT00461552
- Testing
- Leptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV
Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
Study subjects receiving the antiretroviral drugs Combivir or trizivir, will be randomized to switch to Truvada-containing highly active antiretroviral therapy (HAART) or to continue on Combivir or on trizivir.
- Trial name
- TRU (NCT00960622)
- Testing
- Truvada, Combivir, Trizivir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
HIV Infections
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
LC002 is an experimental therapeutic vaccine designed to boost the immune response of people infected with HIV. The purpose of this study was to determine the safety and tolerability of and immune response to LC002 in…
- Trial name
- NCT00270205
- Testing
- LC002 standard vaccination, LC002 high-dose vaccination
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)
This study proposes to evaluate a pre-DHHS guideline of HAART initiation and then de-intensification management strategy in adolescents with mild immunosuppression and compare changes in CD4% from baseline to week 48 and then…
- Trial name
- NCT00491556
- Testing
- Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals.
- Trial name
- NCT00987948
- Testing
- maraviroc (Selzentry)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
HIV Infection
Comparative Study of Three NNRTI-Sparing HAART Regimens
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV infected patients who have never received anti-HIV therapy be treated with a triple drug regimen.
- Trial name
- NCT00811954
- Testing
- Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 1,814 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants.
- Trial name
- NCT00326716
- Testing
- Atazanavir + Ritonavir + Combivir
- Where
- 6 sites in United States, Puerto Rico and 1 more
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Kaletra-isentress Treatment Evaluation
This study will examine the effectiveness and safety of raltegravir (isentress) when used together with lopinavir/ritonavir (kaletra) for the treatment of HIV-infection.
- Trial name
- KITE (NCT00700115)
- Testing
- Kaletra + Isentress, Pre-study antiretroviral regimen
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
HIV Infections
Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya
Given the high mortality associated with infant HIV-1 and the fact that surrogate markers are poorly predictive of mortality risk,empiric highly active antiretroviral therapy (HAART) initiation is started in infants younger than…
- Trial name
- NCT00428116
- Testing
- HAART
- Volunteers
- 140 people
- Sponsor
- University of Washington
HIV Infection
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV-infected people who have never received anti-HIV therapy be treated with a triple drug regimen (commonly called combination antiretroviral…
- Trial name
- NCT00851799
- Testing
- Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir
- Where
- 26 sites in United States
- Volunteers
- 334 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Acquired Immune Deficiency Syndrome Virus
Atorvastatin for HAART Suboptimal Responders
We hypothesise that atorvastatin changes immune activation among HAART-treated adults with suboptimal cluster cell differentiation 4 (CD4) recovery by 25%
- Trial name
- NCT01766076
- Testing
- atorvastatin, Lipitor®
- Volunteers
- 30 people
- Sponsor
- Makerere University
HIV Infections
New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
This is a multi-center, open-label, non-randomized proof-of-concept trial. Two cooperating HIV-specialized centres represented by Dr. med. Hans Jaeger and Prof. Dr.
- Trial name
- NewEra (NCT00908544)
- Testing
- PHI-patients, CHI-patients
- Where
- 8 sites in Germany
- Volunteers
- 47 people
- Sponsor
- MUC Research GmbH
AIDS, HIV Infections
CSP #512 - Options in Management With Anti-Retrovirals
This 'pragmatic' trial is a 2X2 open randomized study of patients in advanced HIV disease who have failed on conventional Highly Active Antiretroviral Therapy (HAART) regimens including all three classes of anti-HIV drugs.
- Trial name
- OPTIMA (NCT00050089)
- Testing
- No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 368 people
- Sponsor
- US Department of Veterans Affairs